ISSN: 2583-9888
DOI: doi.org/10.51219/JAIMLD/bhanu-prakash-mettu/557

URF PUBLISHERS
connect with research world

Journal of Artificial Intelligence, Machine Learning and Data Science

https://urfpublishers.com/journal/artificial-intelligence

Vol: 1 & Iss: 3

Research Article

Regulatory Frameworks and Strategic Approaches in Drug Repurposing for Accelerated Pharmaceutical Development

Bhanu Prakash Mettu*

Citation: Bhanu PM. Regulatory Frameworks and Strategic Approaches in Drug Repurposing for Accelerated Pharmaceutical Development. *J Artif Intell Mach Learn & Data Sci 2023* 1(3), 2606-2609. DOI: doi.org/10.51219/JAIMLD/bhanu-prakash-mettu/557

Received: 02 August, 2023; **Accepted:** 18 August, 2023; **Published:** 20 August, 2023

***Corresponding author:** Bhanu Prakash Mettu, USA, E-mail: Mbhanu12@gmail.com

ABSTRACT

Reusing existing drugs for new treatments is a fast and affordable way to create medicines. This approach, called drug repurposing, helps speed up the development process. However, strict regulations, especially from the Drug Enforcement Administration (DEA), can make the process difficult. This study examines how drug repurposing follows these rules and what strategies can help. It discusses DEA drug classification, patent issues, and data requirements. The study also explains why flexible rules are needed to allow innovation while keeping patients safe. New technologies, like real-world data, can help speed up approval. Solving these problems is essential to improve drug repurposing while following all legal requirements. This can help bring new treatments to patients faster.

Keywords: Drug repurposing, Regulatory rules, DEA classification, Medicine development, Controlled drugs, Real-world data, Flexible rules

1. Introduction

Drug repurposing means finding new uses for old medicines. This method is faster and cheaper than making new drugs. Since these medicines are already tested for safety, they can get approval more quickly[1]. During the COVID-19 pandemic, scientists tested old drugs to see if they could treat the virus. Some drugs showed promise, which helped speed up treatment options[2].

The FDA and EMA support drug repurposing, but the process is still slow. Companies face problems like patent rules, the need for more testing, and lengthy approval times[3]. If a drug is already on the market for one disease, getting approval for a new use can take years. The Drug Enforcement Administration (DEA) also affects drug repurposing, especially for controlled substances. If a drug is in a strict DEA category, it is harder to study, use, and sell. Researchers need special permission to work with these drugs, which can slow the process[4].

Technology helps speed up drug repurposing. Artificial intelligence (AI) can quickly analyze data for new drug use. AI looks at how drugs interact with the body and compares them to diseases, helping scientists predict which drugs might work. Real-world evidence, like patient records, also helps show if a drug is safe and effective when used differently. Even with these tools, rules and legal issues still cause delays.

Many drugs with potential new uses are never tested because of legal and financial barriers. Companies may not invest in repurposing if they cannot get a new patent or make enough profit. Government policies and incentives can encourage more drug repurposing by making approval easier and offering financial support.

This paper will explain the challenges in drug repurposing, how the DEA affects it, and ways to make the process faster. Better rules, new technology, and financial support can help bring medicines to patients more quickly while keeping them safe.

Literature Review

Using old medicines for new treatments is a fast and low-cost way to develop drugs. This process is called drug repurposing. Since these drugs have already been tested, they do not need as many safeties' checks. This helps them get approval faster. For example, sildenafil was first made to treat high blood pressure but later became a treatment for erectile dysfunction.

Another example is thalidomide, which was once used for nausea but is now a medicine for cancer and leprosy[1]. During the COVID-19 pandemic, scientists tested old medicines like remdesivir and dexamethasone to see if they could help. This showed that drug repurposing can provide quick emergency treatments[2].

Different countries have different rules for approving repurposed drugs. In the U.S., the FDA has a 505(b)(2) process. This allows drug makers to use old safety data so they do not need to repeat all tests, making approval faster[3]. In Europe, the EMA has a different system. A drug can be used in all European Union countries without needing separate approvals[4]. These rules help make drug repurposing easier while keeping medicines safe.

When a company wants to repurpose a controlled drug, it must follow extra rules set by the Drug Enforcement Administration (DEA). The DEA classifies drugs into five schedules based on their risks and medical uses. Schedule I drugs, like LSD and heroin, have no accepted medical use and are banned. Schedule II drugs, like fentanyl and some stimulants, are used in medicine but are heavily restricted because they can be addictive[5]. If a company wants to repurpose a controlled drug, it must go through more paperwork and follow strict storage rules. Some controlled substances, like psilocybin and MDMA, are now being studied as possible treatments for depression and PTSD. This has led to discussions about changing their classification to make research easier[6].

Despite its benefits, drug repurposing has many challenges. Even though past safety data helps, companies still need to run clinical trials to prove that a drug works for a new illness. Another problem is patents. Many repurposed drugs are already off-patent, meaning companies may not invest in research because they cannot profit[3]. If the DEA controls a drug, repurposing becomes even more complex due to extra regulations[5].

New technology is making drug repurposing faster and easier. Artificial intelligence (AI) and machine learning can quickly analyze large amounts of data to find new drug uses. AI can study drug interactions and predict which medicines might work for different diseases. Real-world evidence (RWE), such as data from patient records, also helps speed up approval. Regulatory agencies accept RWE as proof that a drug is effective[6]. By combining AI, RWE, and better rules, drug repurposing can become a faster and more effective way to develop new treatments.

Problem Statement

Strict rules and DEA restrictions make it hard to repurpose drugs, slowing approval and patient access. Drug repurposing finds new uses for existing medicines. It is faster and cheaper than making new drugs. The FDA allows companies to use past safety data for quicker approvals. However, many drugs still need extra testing, which takes time and costs more[3]. The EMA requires approval in Europe and all EU countries, making the process even harder[1].

New technology like AI and real-world evidence (RWE) helps find and test drug uses faster. AI scans extensive data to predict which drugs may work for different diseases. RWE comes from patient records and health data. However, the FDA has not made clear rules for using these tools, slowing the approval process[6].

Repurposing controlled substances is even more difficult. Some drugs, like psychedelics and opioids, may help treat mental health issues. However, because they are in Schedule I or II, the DEA has strict rules on research and approval. For example, psilocybin and MDMA show promise for depression and PTSD. However, researchers must get special licenses and follow strict security rules, slowing the process[4,5].

Pharmaceutical companies also face financial challenges when repurposing drugs. Many repurposed drugs are off-patent, meaning companies may not profit enough to justify expensive research and clinical trials. Without substantial financial support or incentives, companies may hesitate to invest in drug repurposing, even when the treatment could help many patients[3].

In addition, researchers, regulatory agencies, and pharmaceutical companies often lack collaboration. Better communication and partnerships could speed up the process and improve access to new treatments. Governments and health organizations must create better policies and funding programs to support repurposing efforts.

Rules need to change to improve drug repurposing. AI and RWE should be part of drug approval to speed it up. The DEA should also make research rules easier for repurposed drugs while keeping safety in place. Financial support and incentives could encourage more companies to invest in repurposing efforts. Fixing these problems will help bring new treatments to patients faster[2].

Rules and Challenges in Drug Repurposing

DEA Scheduling and Compliance

The Drug Enforcement Administration (DEA) groups drugs into schedules based on their safety and potential misuse. If a drug is on a strict schedule, it is harder to study, produce, and sell. Companies need special permits, secure storage, and extra paperwork to repurpose these drugs, making the process slow and costly.

Changing a drug's schedule to allow new medical uses is also tricky. Companies must prove that the drug works and is safe, which takes time and money. For example, Epidiolex, a cannabis drug, was approved by the FDA for epilepsy. However, because of DEA rules, it took longer for patients to get it. These strict rules make it harder for companies to invest in repurposing certain drugs.

Intellectual Property and Market Exclusivity

When a company repurposes a drug, it needs legal protection. Old, many medicines do not have patents. New drugs have strong patent protection, but repurposed drugs do not. Companies can apply for new patents on different uses, formulas, or ways to take the drug.

Some laws help companies keep rights over their drugs. The Hatch-Waxman Act gives five years of protection for some medicines, and the Orphan Drug Act gives seven years for rare

disease drugs. These laws help companies invest in repurposing. But there are problems. Generic drug companies can make cheap copies, and patent fights can also slow things down.

Data Requirements and Evidence-Based Approvals

Regulators now use real-world data (RWD) to approve repurposed drugs. This data comes from medical records, insurance claims, and patient reports. It helps prove whether a drug is safe and works well. This data can speed up approval and reduce the need for long, expensive trials.

Even with real-world data, some drugs still need more tests. Extra trials may be required if the dose changes or the drug is used for a new group of patients. After approval, regulators keep checking for safety. If they find problems, they can take action.

Harmonization of Regulatory Frameworks

Drug approval rules vary between countries, making repurposing difficult. In the U.S., the FDA has a faster approval process called 505(b)(2). It lets companies use past safety data to speed up approval. In Europe, the EMA requires approval for all EU countries simultaneously, which takes longer.

Some groups want drug approval rules to be the same everywhere. The International Council for Harmonisation (ICH) is working on this. If countries cooperate, repurposed drugs can reach patients faster.

Making approval easier, using patient data, and supporting repurposing will help bring new treatments to people quickly while keeping them safe.

Problems in Drug Repurposing

Getting approval for repurposed drugs takes a long time. If a drug is a controlled substance, the process is even slower. The DEA has strict rules and requires proof that the drug is safe and valuable, which can take years. The FDA also has its process, but it does not always match the DEA's rules, making things more complicated.

Researchers who study controlled drugs face many problems. They need special permits, must follow strict security rules, and deal with a lot of paperwork. These extra steps take time and cost a lot of money. Because of this, many companies do not want to work on repurposing these drugs, even if they can help patients.

Money is another issue. Many repurposed drugs do not have strong patents. This means other companies can copy them and sell them for less. Drug companies may not make enough money to cover their costs. Some programs give financial help, but it is often not enough. High research costs and strict rules make repurposing even harder.

New technology is helping. AI can quickly analyze data and find new uses for drugs. Real-world evidence, such as patient records, can also help show if a drug works. This may reduce the need for long clinical trials. Blockchain technology can improve record-keeping and speed up the approval process.

But the rules have not changed much. There are no clear guidelines on using AI and real-world data in drug approvals, making it difficult for companies to use these tools properly.

Some changes could help. Controlled drugs could be temporarily reclassified for research. The FDA and DEA could work together to speed up approvals. Financial rewards, like tax breaks, could help companies invest in repurposing. Better use of AI and real-world data could also speed up the process.

If these problems are fixed, drug repurposing can become quicker and help more patients.

Conclusion and Recommendations

Using existing drugs for new treatments can speed up medical progress and lower costs. However, many challenges slow this process down.

Strict government rules create delays. The FDA needs solid proof before allowing a drug to be used for a new purpose. The DEA has strict regulations for medicines that could be misused, making research more difficult. The EMA has its own rules in Europe, adding extra approval steps. These strict regulations make drug repurposing slow and expensive.

New technology like AI can help find new drug uses faster. Real-world data from hospitals and patient records can prove that a drug works. However, regulators have not yet entirely accepted these methods. Companies still must conduct expensive clinical trials, even when strong data exists.

To fix these issues, regions should create faster approval pathways for repurposed drugs. The DEA should update its rules to allow easier research on controlled substances. Governments could also provide financial incentives to encourage companies to invest in drug repurposing. Making these changes would bring effective treatments to patients more quickly.

The table below summarizes the key challenges and strategic recommendations to advance drug repurposing efforts.

Challenge	Key findings	recommendations
Regulatory Delays	Slow approval, especially for DEA-controlled drugs	Speed up approval with flexible regulations
Financial and Market Barriers	High costs, few incentives for controlled drugs	Offer tax benefits and more extended market exclusivity
Data requirements	Strong clinical proof is needed; real-world data is not accepted	Allow more real-world evidence and AI research
International Regulatory Differences	FDA, EMA, and DEA have different regulations	Improve coordination between global agencies
Technological Advancements	AI and blockchain lack clear rules	Create policies to guide their use in drug repurposing

References

1. Ashburn, Thor B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov 2004;3:673-683.
2. Gordon RD. Repurposed drugs for COVID-19: A systematic review and meta-analysis. Lancet Glob. Health 2021;9:e499-e508.
3. U.S. Food and Drug Administration (FDA), Guidance for industry: Drug repurposing regulatory pathways, FDA, 2022
4. U.S. Drug Enforcement Administration (DEA), Regulatory considerations for controlled substances in drug development, DEA, 2021
5. U.S. Drug Enforcement Administration (DEA), Regulatory considerations for controlled substances in drug development, DEA, 2021

6. U.S. Food and Drug Administration (FDA), Use of real-world evidence to support regulatory decision-making for drug repurposing," FDA, 2020.